Home / Business and Economy / Aurobindo Pharma Unit Boosts Drug Production for MSD
Aurobindo Pharma Unit Boosts Drug Production for MSD
15 Apr
Summary
- TheraNym is expanding its drug substance manufacturing deal with MSD.
- A new 60,000-litre facility will be built with an investment of $150-175 million.
- Aurobindo Pharma's stock saw a 2.63% increase following the announcement.
Aurobindo Pharma's subsidiary, TheraNym Biologics Pvt. Ltd., has significantly expanded its contract manufacturing agreement with Merck Sharp & Dohme (MSD) Singapore Trading Pte Ltd. This expansion involves the creation of a new greenfield drug substance manufacturing facility, designated "Unit 2."
The state-of-the-art facility will feature a substantial bioreactor capacity of 60,000 litres, utilizing mammalian cell culture technology. TheraNym will also integrate the necessary downstream purification infrastructure to ensure comprehensive drug substance production.
This strategic development requires a capital investment estimated between $150 million and $175 million. TheraNym will be responsible for manufacturing and supplying the products to MSD under the terms of their extended arrangement.
The announcement coincided with a positive market reaction for Aurobindo Pharma Ltd., whose stock closed up 2.63% on April 15, 2026. This marks a notable step in TheraNym's growth and its role as a key manufacturing partner for global pharmaceutical companies.
